Upstream Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UPB research report →
Companyupstreambio.com
Upstream Bio, Inc. , a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor.
- CEO
- E. Rand Sutherland
- IPO
- 2024
- Employees
- 52
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $457.67M
- P/E
- -2.91
- P/S
- 137.77
- P/B
- 1.50
- EV/EBITDA
- -2.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.52%
- Op Margin
- -5176.49%
- Net Margin
- -4718.96%
- ROE
- -43.82%
- ROIC
- -56.36%
Growth & Income
- Revenue
- $2.85M · 20.42%
- Net Income
- $-143,443,000 · -128.39%
- EPS
- $-2.66 · -78.52%
- Op Income
- $-160,361,000
- FCF YoY
- -123.30%
Performance & Tape
- 52W High
- $33.68
- 52W Low
- $7.25
- 50D MA
- $9.30
- 200D MA
- $18.63
- Beta
- 1.29
- Avg Volume
- 807.33K
Get TickerSpark's AI analysis on UPB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 16, 26 | GRAY MICHAEL | sell | 852 |
| Mar 16, 26 | Deykin Aaron | sell | 894 |
| Mar 16, 26 | Sutherland Everett Rand | sell | 2,093 |
| Mar 16, 26 | Ambrose Allison | sell | 475 |
| Mar 16, 26 | Houghton Adam | sell | 699 |
| Jan 2, 26 | GRAY MICHAEL | other | 91,500 |
| Jan 2, 26 | GRAY MICHAEL | other | 30,500 |
| Jan 2, 26 | Deykin Aaron | other | 96,000 |
| Jan 2, 26 | Deykin Aaron | other | 32,000 |
| Jan 2, 26 | Ambrose Allison | other | 51,000 |
Our UPB Coverage
We haven't published any research on UPB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate UPB Report →